Four new products have made it onto the European Medicines Agency’s priority medicines (PRIME) scheme, including Kite Pharma’s chimeric antigen receptor T cell (CAR T) therapy, axicabtagene ciloleucel, which has been accepted onto the popular scheme for the second time, for a new indication.
Axicabtagene ciloleucel (KTE-C19) was originally accepted for the treatment of refractory diffuse large B-cell lymphoma (DLBCL). It has now been...







